author-photo

Tatiane Ishida

Bayer HealthCare Pharmaceuticals

1

Papers

1

Citations

Citation Trend

Filter By

Papers (1) Sort By

JournalConferenceOthers

Results of a phase Ib study of regorafenib (REG) 80 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)

© Copyright 2015-2020 Acemap, Inc. Shanghai Jiao Tong University.

沪ICP备18028330号